Novartis joins Dow Chemical backing US drugs maker Sorbent.
The corporate venturing arm of Swiss-based drugs company Novartis has led a $36m extension financing by Sorbent Therapeutics, a US-based pharmaceutical company.
Novartis Ventures joined the extension of Sorbent’s series B round alongside existing investors: venture firms Sofinnova Ventures, Arch Venture Partners, CMEA Capital and AgeChem. The extension funding taking the total raised during the series B to $53m.
Sorbent has previously raised $19m in its series A and seed funding, meaning the company has rased $72m in total.…
